This phase Ib trial tests the safety, side effects, and best dose of gilteritinib when given in combination with ivosidenib or enasidenib in treating patients with FLT3/IDH1 or FLT3/IDH2-mutated acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Change (mutation) in the FLT3 gene can cause tumor cells to grow, and mutations in either the IDH1 or IDH2 genes can cause low blood cell counts. Gilteritinib targets cells that make (express) FLT3, and this targeting action may cause tumor cells to die. Ivosidenib blocks the mutated IDH1 protein and enasidenib blocks the mutated IDH2 protein, which may lead to improved blood cell counts. Giving gilteritinib and ivosidenib or enasidenib may work better in treating patients with FLT3/IDH1 or FLT3/IDH2-mutated acute myeloid leukemia.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05756777.
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose (MTD) and pharmacologically optimal dose for the combination of gilteritinib plus (+) enasidenib (Cohort 2).
II. Determine the safety and tolerability of the combination of gilteritinib + enasidenib (Cohort 2).
SECONDARY OBJECTIVES:
I. The objective is to determine the preliminary efficacy of the combination of gilteritinib + enasidenib (Cohort 2) for the first six cycles.
II. Assess the survival of participants receiving the combination of gilteritinib + enasidenib (Cohort 2) within one year.
III. Participant transfusion requirements.
IV. Participant febrile neutropenia incidence.
EXPLORATORY OBJECTIVES:
I. To assess maturation patterns of leukemic myeloblasts in responding patients as measured by immunophenotypic changes through flow cytometry and morphology.
II. Assess changes in variant allele frequencies (VAF) of IDH2 and FLT3.
III. To describe mutational profiles of patients on the study at screening, response and at relapse, specifically evaluating loss or gain of FLT3 and/or ITD mutations.
IV. To assess 2HG (2-hydroxyglutarate) levels at baseline and following treatment.
V. To assess mechanisms of resistance using single cell analysis.
OUTLINE: This is a dose-escalation study of gilteritinib + ivosidenib (Cohort I - CLOSED 24-FEB-2026), and gilteritinib + enasidenib (Cohort II). Patients are assigned to 1 of 2 cohorts.
COHORT I (CLOSED 24-FEB-2026): Patients with FLT3/IDH1 mutations receive gilteritinib orally (PO) once a day (QD) and ivosidenib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
COHORT II: Patients with FLT3/IDH2 mutations receive gilteritinib PO QD and enasidenib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients also undergo echocardiogram (ECHO) during screening, bone marrow aspiration and biopsy during screening and on study, and collection of blood during screening and on study.
Patients are followed up every 3 months for up to 1 year.
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorEytan M. Stein